BB
KZR

BB Biotech’s Kezar Life Sciences KZR Stock Holding History

BB Biotech’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$21.7M Buy
122,050
+40,207
+49% +$7.92M 0.54% 31
2018
Q4 		$19.3M Buy
+81,843
New +$20M 0.62% 29

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BB Biotech's KZR Position: Q1 2019 in Review

BB Biotech increased its Kezar Life Sciences (KZR) stake by 49% in Q1 2019, buying an estimated $7.92M and bringing the position to 122,050 shares worth $21.7M. The position accounts for 0.54% of the portfolio, ranked #31.

BB Biotech first reported a position in KZR in Q4 2018 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold KZR as of Q1 2019.

  • BB Biotech held 122,050 shares of Kezar Life Sciences worth $21.7M as of Q1 2019.
  • BB Biotech bought 40,207 Kezar Life Sciences shares in Q1 2019, an estimated $7.92M.
  • Kezar Life Sciences made up 0.54% of BB Biotech's portfolio in Q1 2019, its #31 holding.
  • BB Biotech first reported a position in Kezar Life Sciences in Q4 2018 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.